

EXON-INTRON ORGANIZATION OF A GENE FOR PREGNANCY-SPECIFIC  $\beta_1$ -GLYCOPROTEIN, A SUBFAMILY MEMBER OF CEA FAMILY: IMPLICATIONS FOR ITS CHARACTERISTIC REPETITIVE DOMAINS AND C-TERMINAL SEQUENCES

Shinzo Oikawa<sup>1</sup>, Chikako Inuzuka<sup>1</sup>, Goro Kosaki<sup>2</sup> & Hiroshi Nakazato<sup>1</sup>

<sup>1</sup>Suntory Institute for Biomedical Research, Shimamoto-cho,  
Mishima-gun, Osaka 618, Japan

<sup>2</sup>Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo 113, Japan

Received August 18, 1988

---

A fragment of human gene for pregnancy-specific  $\beta_1$ -glycoprotein(s), recently identified CEA family member(s), has been cloned. Analyses of nucleotide and deduced amino acid sequences revealed that it carried, from 5' to 3' direction, exons IA, IB, IIA, IIB, C3, C1 and C2, the first four encoding peptides distinct from but highly similar to domains of PSBGs. The lack of consensus 3' splice site sequence ahead of IB indicated that it was an abortive exon, which would explain the peculiar domain construction of PSBGs, *i.e.* N-IA-IIA-IIB-C1, 2 or 3. Apparently, the multiple C-terminal sequences for a PSBG were generated by alternative splicing among C1, C2 and C3 exons. Furthermore, sequences which overlapped partly with Cexons, were found to be similar to parts of 3'-UTR of CEA and NCA, indicating further the close relationship of CEA/NCA and PSBG subfamily genes.

---


© 1988 Academic Press, Inc.

CEA (1) is one of the most widely used human tumor markers although it lacks absolute tumor specificity because of the presence of a number of immunologically closely related glycoprotein antigens, which comprise CEA family.

Recent success in cloning cDNAs and parts of genomic sequences revealed the existence of multiple genes of highly similar sequences for CEA family (2, 3, 4, 5, 6, 7, & 8). The characteristic domain structures (2, 7) are evident for CEA and NCA of which the former is composed of 108-residue N-domain, three repetitive 178-residue domains I, II and III, and 26-residue hydrophobic M-domain, the latter is composed of 108-residue N-domain, 178 residue domain I and 24-residue M-domain. Domains I, II and III are further subdivided into 92-residue A and 86-residue B subdomains (9). Domain N and subdomains A and B respectively, have been shown to belong to Ig superfamily (9), *i.e.* CEA family belongs to Ig superfamily (3, 9, 10).

---

**Abbreviations:** CEA, carcinoembryonic antigen; NCA, nonspecific crossreacting antigen; PSBG, pregnancy-specific  $\beta_1$ -glycoprotein; UTR, untranslated region; -b, -bases.



**Fig. 1** (A) Sequencing strategy and exon-intron structure of CGM35. The scale is shown at the top in kilobases. Only restriction endonucleases relevant to the present work are shown: B, *Bam* HI; Bg, *Bgl* II; E, *Eco* RI; H, *Hind* III; Ps, *Pst* I; Pv, *Pvu* II; R, *Rsa* I; S, *Sac* I; (E), *Eco* RI linker. Extent and direction of sequencing are shown by arrows. □, exon, but the sequence shown in thin lines may not be an exon; ■, ▨; sequences similar to parts of CEA and NCA cDNA, respectively. (B) Mode of splicing. Thick horizontal lines denote exons, which correspond to those shown in (A).

exons, four of them being translatable into peptides (Fig. 2) highly similar in size and sequence to subdomain As and Bs of CEA family (Fig. 3). However, it should be noted that 3'-splice site preceding "IB" was not conforming to the consensus sequence, suggesting that "IB" might not be processed into mRNA. Other three exons, two of them almost entirely overlapping except for 86-b, apparently encoded C-terminal sequences of this CEA family member. There was no N-domain coding region within entire length of the DNA insert, for CEA N-domain probe did not hybridize to any of the restriction fragments in Southern blot hybridization analysis.

When peptide sequences encoded by each exon were aligned with those of subdomain As and Bs of the members of CEA family deduced from the cloned cDNAs (Fig. 3), and sequence similarities were calculated (Table 1), high similarity, especially to those of PSBGs was evident. Each peptide was 43 to 63% and more than 82% similar to the corresponding subdomains of CEA and NCA, and PSBG, respectively. Apparently, the present gene was of a member of PSBG subfamily rather than of CEA/NCA subfamily. Furthermore, it is significantly more related to PSBG16/93 and C/D than to E. Interestingly, sequence similarity between As or Bs belonging to different repetitive domains, *i.e.* I and II, of PSBGs was only 44 to 49% while that between As or Bs belonging to the same repetitive domains was 80 to 95%. In contrast, subdomains

Recently, primary structure of precursors to two kinds of PSBG was deduced from cloned cDNAs (11), and it was found that the PSBGs belonged to CEA family (12), its domain construction and amino acid sequences being highly similar to CEA and NCA. The precursors comprised, consecutively, 143-residue N-terminal domain including a signal peptide, 93-residue domains IA, IIA and 86 or 88-residue domain IIB and lacked the hydrophobic M-domain. Apparently, domains IA and IIA, and IIB, respectively, are homologous to subdomains A and B of CEA or NCA. The characteristics peculiar to the PSBG is the lack of domain B between IA and IIA, in addition to the lack of M-domain and the presence of two kinds of C-terminal sequences. An apparently identical PSBG with different C-terminus and another PSBG, which was composed of domains N, IA and IIB were recently reported (13).

In this report we will describe cloning and nucleotide sequence of a genomic DNA segment containing introns and exons which encoded sequences highly similar to sub-domain As and Bs of PSBGs. The possible mechanisms generating the peculiar domain construction and different C-termini of PSBGs will be discussed.

## MATERIALS AND METHODS

*Human Genomic Library* — A human genomic library which had been prepared from placental DNA using bacteriophage charon 4A vector as described by Lawn *et al.* (14) was kindly provided by Dr. Masabumi Shibuya of Tokyo University.

*Screening, Subcloning and DNA Sequence Determination* — Approximately one million clones were plated and screened using two  $^{32}\text{P}$ -labeled *Pvu* II fragments of CEA cDNA which corresponded to the repetitive domains of CEA (2). Two positive clones were obtained and the one termed  $\lambda\text{CGM35}$ , was characterized by restriction endonuclease analysis (Fig. 1A). Before subcloning, Southern blot hybridization analysis (15) was performed to locate sequences related to those of cDNA for CEA and NCA using  $^{32}\text{P}$ -labeled probes described below. Only the fragments containing sequences related to those were recloned into M13mp18 or M13mp19 (16) and sequenced by the chain termination method (17).

*Probes* — *Pvu* II-*Acc* I and *Pvu* II-*Pvu* II fragments of pCEA55-2 clone (2) were for N-domain and repetitive domains, respectively. *Rsa* I-*Eco*RI fragment of  $\lambda\text{Kr40}$  (2) and *Eco*RI-*Hind* III fragment of NCA15 (7) were for the sequences related to 3'-UTR of CEA and NCA, respectively. Probes were  $^{32}\text{P}$ -labelled by the nick translation method (18).

## RESULTS AND DISCUSSION

Fig. 1 is a schematic representation of the exon-intron organization of the human genomic clone  $\lambda\text{CGM35}$ , also depicted is the subcloning and sequencing strategy of the DNA fragment. Amino acid sequences translatable from the three frames of the DNA fragments were deduced and compared with those of CEA and NCA to identify exons. The consensus sequences at 5'- and 3'-splice sites (19, 20) were also referred to in order to locate the exon-intron boundaries. As is shown in Fig. 1, there were seven putative






CTGCAGCAAAAAATACCTTGGCGGCCAAAGTAAAGACTGAAACTAAGCAAGATTCAGCAGCTGCATGCTCCAAAGTACGAGCACAAGGTCGGCCGAGCGGCACTTGGACAGCGGAGGACT 120


CACAGACGGCAACAGGGGGCTGTGACTGCTGCTGCTGCTTTTCCATACGCCAATCTGCTGCTCAATTACACTTGCAGAACTCTGCTGTTTCTACATGAAGCAGCGGCTCACAACCTC 240

TGAGCCCTCAGATTGCCCTGCATCTGCTTGCACACACACACCTGCCATGGGCTTTTAAAGCACTTGGTGGGCTCAGAGCTGGGAAATGCCAATCTGATTGAAAATGCCCTTGGAGG 360

AATCAAAGCTGCCACACAGGCCAATCTCTCTCTGTTTCTGCAAGCTGCAGACTCCGACCCCTCCATCTCCAGCAGCAAAATTAACCCCGAGGAGCCCATCGAGGCTGTGAGCTTAAC 480

+GluThrProLysProSerLysLeuAsnGluMetGluAlaThrLeu 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350 360 370 380 390 400 410 420 430 440 450 460 470 480 490 500 510 520 530 540 550 560 570 580 590 600 610 620 630 640 650 660 670 680 690 700 710 720 730 740 750 760 770 780 790 800 810 820 830 840 850 860 870 880 890 900 910 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540 1550 1560 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680 1690 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820 1830 1840 1850 1860 1870 1880 1890 1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 2050 2060 2070 2080 2090 2100 2110 2120 2130 2140 2150 2160 2170 2180 2190 2200 2210 2220 2230 2240 2250 2260 2270 2280 2290 2300 2310 2320 2330 2340 2350 2360 2370 2380 2390 2400 2410 2420 2430 2440 2450 2460 2470 2480 2490 2500 2510 2520 2530 2540 2550 2560 2570 2580 2590 2600 2610 2620 2630 2640 2650 2660 2670 2680 2690 2700 2710 2720 2730 2740 2750 2760 2770 2780 2790 2800 2810 2820 2830 2840 2850 2860 2870 2880 2890 2900 2910 2920 2930 2940 2950 2960 2970 2980 2990 3000 3010 3020 3030 3040 3050 3060 3070 3080 3090 3100 3110 3120 3130 3140 3150 3160 3170 3180 3190 3200 3210 3220 3230 3240 3250 3260 3270 3280 3290 3300 3310 3320 3330 3340 3350 3360 3370 3380 3390 3400 3410 3420 3430 3440 3450 3460 3470 3480 3490 3500 3510 3520 3530 3540 3550 3560 3570 3580 3590 3600 3610 3620 3630 3640 3650 3660 3670 3680 3690 3700 3710 3720 3730 3740 3750 3760 3770 3780 3790 3800 3810 3820 3830 3840 3850 3860 3870 3880 3890 3900 3910 3920 3930 3940 3950 3960 3970 3980 3990 4000 4010 4020 4030 4040 4050 4060 4070 4080 4090 4100 4110 4120 4130 4140 4150 4160 4170 4180 4190 4200 4210 4220 4230 4240 4250 4260 4270 4280 4290 4300 4310 4320 4330 4340 4350 4360 4370 4380 4390 4400 4410 4420 4430 4440 4450 4460 4470 4480 4490 4500 4510 4520 4530 4540 4550 4560 4570 4580 4590 4600 4610 4620 4630 4640 4650 4660 4670 4680 4690 4700 4710 4720 4730 4740 4750 4760 4770 4780 4790 4800 4810 4820 4830 4840 4850 4860 4870 4880 4890 4900 4910 4920 4930 4940 4950 4960 4970 4980 4990 5000 5010 5020 5030 5040 5050 5060 5070 5080 5090 5100 5110 5120 5130 5140 5150 5160 5170 5180 5190 5200 5210 5220 5230 5240 5250 5260 5270 5280 5290 5300 5310 5320 5330 5340 5350 5360 5370 5380 5390 5400 5410 5420 5430 5440 5450 5460 5470 5480 5490 5500 5510 5520 5530 5540 5550 5560 5570 5580 5590 5600 5610 5620 5630 5640 5650 5660 5670 5680 5690 5700 5710 5720 5730 5740 5750 5760 5770 5780 5790 5800 5810 5820 5830 5840 5850 5860 5870 5880 5890 5900 5910 5920 5930 5940 5950 5960 5970 5980 5990 6000 6010 6020 6030 6040 6050 6060 6070 6080 6090 6100 6110 6120 6130 6140 6150 6160 6170 6180 6190 6200 6210 6220 6230 6240 6250 6260 6270 6280 6290 6300 6310 6320 6330 6340 6350 6360 6370 6380 6390 6400 6410 6420 6430 6440 6450 6460 6470 6480 6490 6500 6510 6520 6530 6540 6550 6560 6570 6580 6590 6600 6610 6620 6630 6640 6650 6660 6670 6680 6690 6700 6710 6720 6730 6740 6750 6760 6770 6780 6790 6800 6810 6820 6830 6840 6850 6860 6870 6880 6890 6900 6910 6920 6930 6940 6950 6960 6970 6980 6990 7000 7010 7020 7030 7040 7050 7060 7070 7080 7090 7100 7110 7120 7130 7140 7150 7160 7170 7180 7190 7200 7210 7220 7230 7240 7250 7260 7270 7280 7290 7300 7310 7320 7330 7340 7350 7360 7370 7380 7390 7400 7410 7420 7430 7440 7450 7460 7470 7480 7490 7500 7510 7520 7530 7540 7550 7560 7570 7580 7590 7600 7610 7620 7630 7640 7650 7660 7670 7680 7690 7700 7710 7720 7730 7740 7750 7760 7770 7780 7

**Fig. 2** Nucleotide sequence and deduced amino acid sequence of CGM35. Nucleotides are numbered beginning from *Pst* I site (1-1358) and *Pvu* II site (1'-2749') of the sequenced fragments (Fig. 1A). Sequences containing exons are shown on the right by ]. Consensus splice site sequences are boxed, with  being non-conforming sequence. IB which may be an abortive exon is shown by broken ], and amino acids deduced are parenthesized. Amino acids are numbered beginning from the first residue of exon 1A, through the C-terminal residues of exon C1, C2 or C3. , ; start and end of the sequence resembling to that of a part of the cDNA indicated; PS8G, PS8G1 6/93 (9); E, C, PS8GE and C(13), respectively; (E), not highly but moderately similar to E, , *Alu* family insert seen in the case of CEA; , poly A addition site. Putative poly A signals are underlined. Nucleotides 1788' and 2676' are ambiguous.



**Fig. 3** Comparison of the domains of CGM35 with those of CEA family. Only amino acids different from those of CEA I are shown in single notation. Dashes mean identity. Arrow indicates boundary between A and B subdomains. Underlined sequence is probably not expressed in the protein. The last residues of CGM35 II and PSBG are D, E or A due to the presence of three kinds of C-terminal coding sequences. Possible N-glycosylation sites are boxed. PSBGC/D are different from PSBG only at amino acid 82 in II. PSBG stands for PSBG16/93.

belonging to different repetitive domains of CEA/NCA subfamily, were more than 72% similar with the exception of CEA IIIB which were about 60% similar to CEA IB, IIB and NCA IB (Fig. 3). These results clearly indicate that divergence among repetitive domains are greater in PSBG subfamily than in CEA/NCA subfamily. In view of this, CGM35 IB had no counterpart among PSBGs whose primary structure had been deduced from the cloned cDNAs. It was noted that there was no putative N-glycosylation site in subdomain Bs of PSBG, albeit the presence of several of ones in other subdomains (Fig. 3).

Watanabe and Chou isolated two cDNA clones, PSBG16 and 93, encoding human PSBGs of 417 and 419 amino acids, respectively (11). The sequenced portions of these cDNAs were identical with the exception that PSBG93 contained an additional 86-b at the end of the common 3'-coding region. This resulted in the generation of two C-terminal sequences after common 414 amino acids, which were EAL and DWTVP, for PSBG16 and 93, respectively. More recently, three PSBGs deduced from cloned cDNAs were reported (13). PSBGD was virtually identical to PSBG93 with only three amino acids

**Table I.** Amino acid similarities between subdomain As and Bs of CGM 35, PSBG 16/93(12), PSBG E(13), CEA(2) and NCA(7). PSBG stands for PSBG 16/93 which is virtually identical to PSBG C/D (13). The number of matches is expressed as per cent of the similarity length.

**A Subdomain**

		CEA		NCA	CGM35		PSBG		PSBG E
		II	III	I	I	II	I	II	I
CEA	I	73.9	83.7	81.5	59.8	53.3	58.7	53.3	55.4
CEA	II		76.1	79.3	57.6	53.3	56.5	55.4	55.4
CEA	III			85.9	58.7	55.4	57.6	55.4	58.7
NCA	I				63.0	56.5	62.0	58.7	59.8
CGM35	I					45.7	93.5	47.8	88.0
CGM35	II						46.7	95.7	46.7
PSBG	I							48.9	88.0
PSBG	II								48.9

**B Subdomain**

		CEA		NCA	CGM35		PSBG	PSBG E
		II	III	I	I	II	II	II
CEA	I	72.1	60.5	86.0	46.5	57.0	53.5	59.3
CEA	II		58.1	73.3	47.7	57.0	55.8	60.5
CEA	III			60.5	43.0	50.0	47.7	51.2
NCA	I				46.5	58.1	54.7	60.5
CGM35	I					47.7	44.2	48.8
CGM35	II						93.0	82.6
PSBG	II							77.9

differences. PSBGC shared 414 N-terminal amino acids with PSBGD but followed by an entirely different C-terminal sequence of 14 amino acids, AYSSSINYTSQNRN. PSBGE was composed of N-domain and subdomains IA and IIB which were distinct from but highly similar to corresponding domains of other PSBGs.

Interestingly, three exons of CGM35 contained sequences which could generate three kinds of mRNA by differential splicing (Fig. 1B). As is shown in Fig. 2, C3 exon at nucleotides 1475'-2034' encoded 12-residue C-terminal sequence, whose first 9 residues were identical to those of PSBGC. C1 and C2 exons starting at nucleotides 2076' and 2162', respectively, were identical except for the extra 86-nucleotides at 5'-terminus of C1 exon. C1 and C2 exons, respectively, would encode C-terminal sequences, DWILP and EAL, which were virtually identical to those of PSBG93/D(11, 13) and 16 (11), respectively. In addition to the C-terminal amino acid sequence similarities, C1, C2 and C3 exons are highly similar, *i.e.* >93%, in nucleotide sequence to 3'-end of PSBG93/D, 16 and C, respectively (Fig. 4). The sequence related to 3'-end of PSBGE was also found but

(A)

```

                                *      *      *      *      *
CGM35      AGTCTATCTGGCCTTCAGGGAGAGTCAAGGAAACATTTTATTCCC
PSBG E      CT...TC...CT...A.TCC...C.TAGCA.CTGTG..G.CAT...TG

                                *      *      *      *      *
CGM35      AGCCTGCGTCCCATGGGCACAAG-CAAATCCCAATTCTCCTCCTA-AACCCTCCAA---ATTGTCTAA
PSBG E      TATT.CA.GAAG.CT...GG...ATTT..GGA...GG...T.A.A.GG..T..TG..TAC.AGCTC..G.
CEA        .....G.

                                *      *      *      *      *
CGM35      GAACCTTTGAACCTTTAACAACAGGCTGATATC-TTCATAA---AATTCACAGCTAGACCAAGCAG-
PSBG E      T...-.C..G.-.CAT..C.CTG.A..A.G.A.T...A..TTT...GAA...G..GATA.CTT..T-
CEA        ...T..CC...TG...TAA...C.G.-...G...-.C.GT.CA..A..T...A

                                *      *      *      *      *
CGM35      GAAAAAC-ATTGATTTCAATGAATAATTGATAATAAT-GAGGATAATGTTTTATGA-TTTTCATTGA
PSBG E      ....TT.A.GAC.AAGA.GAA...C.CA..GT..T.G..CT.A.TAA.CAAA.G...AA.G...C.
CEA        ....TA...A...TG.G.C..A...C...-...A...C..A..T...T...

                                *      *      *      *      *
CGM35      AAATTTGCTGATTCCTTAATGGTTTGTCTTCTACA-TTGACGGAA-TTTTCTCTTTTACCTATCTGT
PSBG E      T....T...-.GA...TGC..A..CT.GG.-A..-TTTC...C.C.AGA...TGAACT..T.
CEA        ..T...TC...C.C.G.T..C.G.A..C...T...G...CAC

                                *      *      *      *      *
CGM35      AGCTTATAGCAGTTCAATAACTATACCGCAGTTTATGAACTGTAAATGAATATTACTTTTGCTTTC
PSBG E      TT...-G...-A.TGG...G...-...C...TG.A...AAA...C...C...C...C...
CEA        ...C...A..TG...A...-...C...TG...AAA...G.C..A..T...CC.
PSBG C      ...-...C...CTGG...C...C...C...C...C...

                                *      *      *      *      *
CGM35      TACCTGACTGCCCGAATTGGGCAACTATTCATGAGATTGATATGTTTATGGTAATACACATATTTC
PSBG E      ..T...G...T...A.T...T...C...A...GC...
CEA        ..TG..GTC..T...C...A...AT..T...-G...T.GT...
PSBG C      ...

                                *      *      *      *      *
CGM35      ACAAGTACAGCAACATCTGCTCTCTTTGTACAGGACACATTTCAATCATTTGTTATATTACCAAGGC
PSBG E      ...T..[Poly A]
CEA        ...T..AT..A...T.G.A.G...A.T...G...A...A...
PSBG C      ...T...T...T...T...G...T...

                                *      *      *      *      *
CGM35      TTGACTGGGATGTTATATTTAAGGATATAGA---TA--GAATGAACAGGTATGAAGTCCAGGCAAGT
CEA        ...A.A...CG...G...A.CCCA..GGT...A...CAC.G.T...A...AA...
PSBG C      ...T.C...-..AA.C...-...-...-...A...

                                *      *      *      *      *
CGM35      CTGAAGTCAGCCTTGCTTGGCTTCTATTCTCAA-GAGTTTGTAAAGTTTAACTCAGATTCTTAT
CEA        .....G.G...TT.AAC..C...
PSBG C      .....G...G...GA...

                                *      *      *      *      *
CGM35      AAAAAGCTTAGAGAAAGGAAATTTTAA[---Gap---]GAGAGCCTACACGGTCCATTGCTACTCTTG
CEA        .....CC..C...-C..C...[Alu 303-b]A.A..T...TGT...AG.CA...
PSBG C      .....G..[---Gap---]...C...T...

                                *      *      *      *      *
CGM35      CTGCACCTATGTAACCACTAGACCCAGTTTGAAGAACTCAACCTATTTTGCAACAACTTATCTAC
CEA        ...G...A...G...G...A..C...T...A..A..T...A...[Poly A]
PSBG C      ...A...C...C...

                                *      *      *      *      *
CGM35      TGAATTATCATTTGTTAAACTAGAGATGCCCATAGAGAGAAAAATTATGTGGAATTAATAACTGTAGT
PSBG C      .....G...G...

                                *      *      *      *      *
CGM35      ACACCTGTTATGAGATTGC
PSBG C      .T...C...[Poly A]

```

**Fig. 4.** Nucleotide alignments of similarities in the 3'-end between CGM 35 and members of CEA family. (A) CGM 35 (nucleotides 1162'-2033'), PSBGE(982-1440) (13), CEA (2499-3468) ((2), nucleotides 2930-3468 are our unpublished data) and PSBGC(1244-1796) (13) are aligned. (B) CGM 35 (2074'-2749'), PSBG16/93 (1310-1906, with additional 86-b seen in PSBG93, which are underlined) (11) and NCA (1074-1520) (7) are aligned. PSBGD(1242-1928) is almost identical to PSBG16/93 except for the portion shown in last line. Identical residues and deletions are shown by dots and dashes, respectively. ↓, poly A addition site. Poly A signals are underlined.

(B)

```

      *      *      *      *      *      *
CGM35  AGACTGGACATTACCTGAATTCTACTAGTTCCTCCAATTCATTTTCTTCCATGGAAATCGCTAAGAAAA
PSBG16 T...G.T.....A.....C.....A.....GC
NCA    ...T...CAG...T...C.....C.....C.A...A..C.
      *      *      *      *      *      *
CGM35  AGACCCACTCTGTTCCAGAGCCCTATAGCTGGAGGTGGACARCTCAATGTAATTTTCATGGGAAACC
PSBG16 ..GT.TG...C...T.....T.....A.....A.....A.A.....
NCA    ..GT.TG...C...T.....T.....A.....A.....A.A.....
      *      *      *      *      *      *
CGM35  CTTGTACCTGAAGCGTGAAGCCACTCAGAACTCACTAAATGTTGACACCATAAACAACAGATGCTCAAAC
PSBG16 .....C.....A.....C.....A.....A.....A.....A.....
NCA    ..CAGG...G.T...T.....G.....G.....T.G...CAG.....
      *      *      *      *      *      *
CGM35  TGTAAACCAGGACAATAAGTGGAATGACTTCACACTGTGGACAGTTTTTCCCAAGATGTCAGAACAGACT
PSBG16 .....C.....C.....C.....C.....C.....C.....C.....
NCA    ..C.....T.GTG..G..A.T..C.....A.....C.....A.....A.....
      *      *      *      *      *      *
CGM35  CCCCATCATGATGAGGCTCTCACCCC-TCTTAAC-TGTCTTGCTCATGCTGCCTCTTTCACCTTGGCAG
PSBG16 .....C.....C.....C.....C.....C.....C.....C.....
NCA    ..T.....A.....T.....C.T...TT.....T.....G.....
      *      *      *      *      *      *
CGM35  GATAATGCAGTCATTAGAAATTTACATGATAGCTTCTGAGGGTAAC--AATAGAGTGTGAGATATGTC
PSBG16 .....C.....A.....C.....C.....C.....C.....C.....
NCA    ..G...T.....T.....A.A.....A.....TT..C.....C.A..
      *      *      *      *      *      *
CGM35  ATCTCAA-CCCAAACTTTTACATAACATCTCAGGGGGAATGTGGCTCTCTCCACCTTGATACAGGACT
PSBG16 .....C.T.....C.....A.....AAGAGATCCTTTA
NCA    T.G...T...CG.....A.....AAGAGATCCTTTA
      *      *      *      *      *      *
CGM35  CCCAATAGAATGAACACAGAGATATTGCCCGTGTGTTTGCAGATAGATGGTTTCTATGAAGAGGATAGG
PSBG16 .....G.....G.....G.....C.....
      *      *      *      *      *      *
CGM35  AAAGCTGAATATATATAGAGTCCCCTTTAAATGCACATTCTGTGGATGTCTC--GCCATTTCTAAGAG
PSBG16 .....C.....G.....G.....TT..G.....
      *      *      *      *      *      *
CGM35  ATACATTGTAATAATGTGACAGTAACTACTGATTCTAGCAGATAAACATGTAC
PSBG16 .....C.....G.....CACCTCCC[EcoR I]
PSBG D .....C.....G.....TTGCT[Poly A]

```

Figure 4 - Continued.

it was separable into two portions, the 5'- and 3'-end sequences comprising nucleotides 1164'-1489' and 1490'-1620' were 47.6% and 80.2% similar to corresponding PSBG E sequences, respectively. The 3'-end sequence was where similarity between 3'-end sequences of PSBG C and PSBG E was found (13). Although 5'-end sequence could encode 35-residue peptide if it was processed into mRNA, the significance of these findings is not clear at this time.

In addition to the similarities found between 3'-end sequences of members of PSBG subfamily, CGM 35 contained sequences highly similar, *i.e.* >76%, to 3'-UTR of CEA and NCA. The CEA and NCA like sequences overlapped partly with exons C3 and C1, 2, respectively (Fig. 2). The corresponding CEA sequence started about 40-residue downstream of the first *Alu* sequence, extended beyond the poly A addition site of the shorter cDNA (2) and ended at the poly A addition site of the longer cDNA (Fig. 4A). The second *Alu* sequence of 303-b found in the longer cDNA (details will be published elsewhere) was missing in the CGM 35 sequence (Fig. 2 & 4A). The NCA sequence started from 40-b downstream of the stop codon, *i.e.* where similarity between NCA and CEA cDNA ceased (7). The sequence similarity of parts of 3'-UTR of cDNAs of PSBG D and NCA was already noted (13). In spite of these similarities, sequences similar to those corresponding to M-



domains of CEA or NCA were not found. These results, along with the finding that none of the known PSBGs including CGM 35 has C-terminal hydrophobic M-domain, might indicate that M-domains of CEA/NCA subfamily are encoded by separate exons.

In conclusion, CGM 35 clone carried a sequence which contained most of a gene for a new member of PSBG subfamily within CEA family. As is summarized in Fig. 1A, the N-domain truncated sequence consisted of exons IA, IB, IIA, IIB, C3, C1 and C2, from 5' to 3' direction. As discussed above, exon IB was apparently an abortive exon which would not be processed into mRNA. Alternative splicing will generate at least three kinds of mRNA which encode PSBGs having three different C-terminal sequences. Thus, at least three PSBGs, (N)-IA-IIA-IIB-C1, (N)-IA-IIA-IIB-C2 and (N)-IA-IIA-IIB-C3, which are distinct from but highly similar to PSBG93/D, 16 and C, respectively, will be produced. In addition, it is possible that the fourth PSBG having C-terminal sequence derived from the E-like sequence would be found. Another implication of the present findings is that, PSBGE(13) having N-IA-IIB-CE construction might be encoded by a gene having two consecutive abortive exons, namely "IB" and "IIA", although other mechanisms such as alternative splicing can not be excluded.

Finally, considering the highly conserved domain structures among CEA family members, it is conceivable that genes for the members are similarly constructed, *i.e.* each domain and subdomain are encoded by separate exons like in immunoglobulin and T cell receptors, introns between A and B are rather short and those between N and A, and B and A are rather long.

#### REFERENCES

1. Gold, P. & Freedman, S. Q. (1965) *J. Exp. Med.* 121, 439-462
2. Oikawa, S., Nakazato, H., & Kosaki, G. (1987) *Biochem. Biophys. Res. Commun.* 142, 511-518
3. Zimmermann, W., Ortlieb, B., Friedrich, R. & von Kleist, S. (1987) *Proc. Natl. Acad. Sci. USA.* 84, 2960-2964
4. Beauchemin, N., Benchimol, S., Cournoyer, D., Fuchs, A. & Stanners, C. P. (1987) *Mol. Cell. Biol.* 7, 3221-3230
5. Thomson, J. A., Pande, H., Paxton, R. J., Shively, L., Padma, A., Simmer, R. L., Todd, C. W., Riggs, A. D. & Shively, J. E. (1987) *Proc. Natl. Acad. Sci. USA.* 84, 2965-2969
6. Oikawa, S., Kosaki, G. & Nakazato, H. (1987) *Biochem. Biophys. Res. Commun.* 146, 464-469
7. Tawaragi, Y., Oikawa, S., Matsuoka, Y., Kosaki, G. & Nakazato, H. (1988) *Biochem. Biophys. Res. Commun.* 150, 89-96
8. Neumaier, M., Zimmermann, W., Shively, L., Hinoda, Y., Riggs, A. D. & Shively, J. E. (1988) *J. Biol. Chem.* 263, 3202-3207
9. Oikawa, S., Imajo, S., Noguchi, T., Kosaki, G. & Nakazato, H. (1987) *Biochem. Biophys. Res. Commun.* 144, 634-642

10. Paxton, R. J., Mooser, G., Pande, H., Lee, T. D., & Shively, J. E. (1987) *Proc. Natl. Acad. Sci. USA.* 84, 920-924
11. Watanabe, S. & Chou, J. Y. (1988) *J. Biol. Chem.* 263, 2049-2054
12. Watanabe, S. & Chou, J. Y. (1988) *Biochem. Biophys. Res. Commun.* 152, 762-768
13. Streydio, C., Lacka, K., Swillens, S. & Vassart, G. (1988) *Biochem. Biophys. Res. Commun.* 154, 130-137
14. Lawn, R. M., Fritsch, E. F., Parker, R. C., Blake, G. & Maniatis, T. (1978) *Cell* 15, 1157-1174.
15. Southern, E. M. (1975) *J. Mol. Biol.* 98, 503-517
16. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) *Gene*, 33, 103-119
17. Sanger, F., Nicklen, S. & Coulson, A. R. (1975) *Proc. Natl. Acad. Sci. USA*, 72, 3961-3965
18. Rigby, P. W. J., Dieckmann, M., Rhodes, C. and Berg, P. (1977) *J. Mol. Biol.* 113, 237-251
19. Chambon, P. & Breathnach, R. (1981) *Ann. Rev. Biochem.* 50, 349-383
20. Shapiro, M. B. & Senapathy, P. (1987) *Nucl. Acids Res.* 15, 7155-7174